PTO- 1478 |
Approved for use through 02/28/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 90535780 |
Filing Date: 02/19/2021 |
Input Field |
Entered |
SERIAL NUMBER | 90535780 |
---|---|
MARK INFORMATION | |
*MARK | VISTAGEN |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | VISTAGEN |
MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size, or color. |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | VistaGen Therapeutics, Inc. |
*MAILING ADDRESS | 343 Allerton Avenue |
*CITY | South San Francisco |
*STATE (Required for U.S. applicants) |
California |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
94080 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Nevada |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceuticals; Human and veterinary preparations for medical uses; Medical and pharmaceutical preparations and products for use in the treatment of humans and animals. |
FILING BASIS | SECTION 1(b) |
ADDITIONAL STATEMENTS SECTION | |
ACTIVE PRIOR REGISTRATION(S) | The applicant claims ownership of active prior U.S. Registration Number(s) 2787886. |
ATTORNEY INFORMATION | |
NAME | David Lipson |
ATTORNEY DOCKET NUMBER | 128.T001US01 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | J.A. Lindeman & Co. |
STREET | 3190 Fairview Park Drive, Suite 1070 |
CITY | Falls Church |
STATE | Virginia |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 22042 |
EMAIL ADDRESS | david.lipson@jalindeman.com |
CORRESPONDENCE INFORMATION | |
NAME | David Lipson |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | david.lipson@jalindeman.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | mail@jalindeman.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 350 |
*TOTAL FEES PAID | 350 |
SIGNATURE INFORMATION | |
ORIGINAL PDF FILE | hw_129213201239-120052140 _._2021-02-08_Section_1_b __Declaration__VISTAGEN_.pdf |
CONVERTED PDF FILE(S) (1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\905\357\90535780\xml1\ APP0003.JPG |
SIGNATORY'S NAME | Shawn K. Singh |
SIGNATORY'S POSITION | Chief Executive Officer, VistaGen Therapeutics, Inc. |
SIGNATURE METHOD | Handwritten |
PTO- 1478 |
Approved for use through 02/28/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 90535780 |
Filing Date: 02/19/2021 |
The applicant's current Correspondence Information: |
David Lipson |
PRIMARY EMAIL FOR CORRESPONDENCE: david.lipson@jalindeman.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): mail@jalindeman.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |